CY1124911T1 - Συνθεσεις πεπτιδιων και μεθοδοι χρησης - Google Patents

Συνθεσεις πεπτιδιων και μεθοδοι χρησης

Info

Publication number
CY1124911T1
CY1124911T1 CY20221100088T CY221100088T CY1124911T1 CY 1124911 T1 CY1124911 T1 CY 1124911T1 CY 20221100088 T CY20221100088 T CY 20221100088T CY 221100088 T CY221100088 T CY 221100088T CY 1124911 T1 CY1124911 T1 CY 1124911T1
Authority
CY
Cyprus
Prior art keywords
methods
peptide compositions
compositions
photoreceptors
fas
Prior art date
Application number
CY20221100088T
Other languages
Greek (el)
English (en)
Inventor
Cagri G. BESIRLI
Alexander J. Bridges
John K. FRESHLEY
William A. Hunke
Linda L. JOHNSON
Francis X. Smith
Ethan SYLVAIN
David N. ZACKS
Original Assignee
Onl Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics, Inc. filed Critical Onl Therapeutics, Inc.
Publication of CY1124911T1 publication Critical patent/CY1124911T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CY20221100088T 2015-05-01 2022-02-02 Συνθεσεις πεπτιδιων και μεθοδοι χρησης CY1124911T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (1)

Publication Number Publication Date
CY1124911T1 true CY1124911T1 (el) 2023-01-05

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100088T CY1124911T1 (el) 2015-05-01 2022-02-02 Συνθεσεις πεπτιδιων και μεθοδοι χρησης

Country Status (21)

Country Link
US (5) US10508134B2 (cg-RX-API-DMAC7.html)
EP (3) EP4623925A3 (cg-RX-API-DMAC7.html)
JP (2) JP6884755B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240046280A (cg-RX-API-DMAC7.html)
CN (2) CN113651873B (cg-RX-API-DMAC7.html)
AU (1) AU2016258837B2 (cg-RX-API-DMAC7.html)
CA (1) CA2984154A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124911T1 (cg-RX-API-DMAC7.html)
DK (1) DK3288379T3 (cg-RX-API-DMAC7.html)
EA (2) EA035293B1 (cg-RX-API-DMAC7.html)
ES (1) ES2906173T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220138T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057883T2 (cg-RX-API-DMAC7.html)
LT (1) LT3288379T (cg-RX-API-DMAC7.html)
MX (1) MX387317B (cg-RX-API-DMAC7.html)
PL (1) PL3288379T3 (cg-RX-API-DMAC7.html)
PT (1) PT3288379T (cg-RX-API-DMAC7.html)
RS (1) RS62866B1 (cg-RX-API-DMAC7.html)
SI (1) SI3288379T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200069T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016178993A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3288379T1 (sl) 2015-05-01 2022-06-30 Onl Therapeutics, Inc. Peptidne sestave in načini uporabe
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CN115119501A (zh) * 2019-12-18 2022-09-27 细胞疗法有限责任公司 包含神经营养剂、凋亡信号传导片段抑制剂(FAS)或FAS配体(FASL)抑制剂、肿瘤坏死因子-α(TNF-α)或TNF受体抑制剂、线粒体肽、寡核苷酸、趋化因子抑制剂或半胱氨酸-天冬氨酸蛋白酶抑制剂的药物递送系统
US20240285724A1 (en) * 2021-06-15 2024-08-29 Onl Therapeutics, Inc. Methods and compositions for treating ocular disorders and diseases
AU2022311780A1 (en) * 2021-07-13 2024-02-08 Onl Therapeutics, Inc. Methods and compositions for improving visual function in ocular diseases and disorders
EP4456908A4 (en) * 2021-12-27 2025-08-27 Onl Therapeutics Inc SFASL TO INHIBIT RPE CELL DEATH AND ASSOCIATED DISORDERS
EP4565595A2 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
EP4698204A1 (en) * 2023-04-19 2026-02-25 ONL Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 C末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
WO2005117940A2 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
SI1885336T1 (sl) * 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
AU2006320327A1 (en) 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
EP2222696A1 (en) * 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
EP2403937B1 (en) 2009-03-03 2015-05-06 The Regents of the University of Michigan Use of met peptide for inhibiting photoreceptor apoptosis
EA201171188A1 (ru) * 2009-03-30 2012-05-30 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство против болезни сетчатки и способ профилактики или лечения болезни сетчатки с использованием jnk (c-jun-аминоконцевая киназа)-ингибиторного пептида, а также применение указанного пептида
JP2013501064A (ja) * 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
TW201542231A (zh) * 2011-06-06 2015-11-16 Kineta One Llc 以shk為主之醫藥組合物及其製備方法及用途
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
WO2013191352A1 (en) * 2012-06-21 2013-12-27 Hanall Biopharma Co., Ltd. New uses of modified human tumor necrosis factor receptor-1 polypeptide
WO2014071183A1 (en) * 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
SI3288379T1 (sl) 2015-05-01 2022-06-30 Onl Therapeutics, Inc. Peptidne sestave in načini uporabe
US20190240353A1 (en) 2016-07-05 2019-08-08 University Of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
US20210121534A1 (en) 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
HRP20220138T1 (hr) 2022-05-27
EP3288379B1 (en) 2021-11-03
US20210094985A1 (en) 2021-04-01
CN113651873A (zh) 2021-11-16
US12258425B2 (en) 2025-03-25
RS62866B1 (sr) 2022-02-28
EP3288379A4 (en) 2018-10-24
KR102652804B1 (ko) 2024-04-01
KR20170140383A (ko) 2017-12-20
WO2016178993A1 (en) 2016-11-10
EP4623925A2 (en) 2025-10-01
AU2016258837A1 (en) 2017-11-09
DK3288379T3 (da) 2022-02-07
JP2021120400A (ja) 2021-08-19
US20180291062A1 (en) 2018-10-11
BR112017023479A2 (pt) 2018-07-24
CN113651873B (zh) 2025-09-02
ES2906173T3 (es) 2022-04-13
US20200123201A1 (en) 2020-04-23
MX2017014075A (es) 2018-07-06
US20230287052A1 (en) 2023-09-14
KR20240046280A (ko) 2024-04-08
EP3288379A1 (en) 2018-03-07
PT3288379T (pt) 2022-02-08
US20250346631A1 (en) 2025-11-13
EP3997981A1 (en) 2022-05-18
LT3288379T (lt) 2022-02-25
SI3288379T1 (sl) 2022-06-30
CN107708416A (zh) 2018-02-16
MX387317B (es) 2025-03-18
CA2984154A1 (en) 2016-11-10
HUE057883T2 (hu) 2022-06-28
HK1251979A1 (zh) 2019-05-10
CN107708416B (zh) 2021-06-29
EA035293B1 (ru) 2020-05-26
EA201792399A1 (ru) 2018-05-31
EP4623925A3 (en) 2026-02-11
EA202090184A3 (ru) 2020-07-31
US10508134B2 (en) 2019-12-17
EA202090184A2 (ru) 2020-05-31
US10829518B2 (en) 2020-11-10
PL3288379T3 (pl) 2022-03-07
AU2016258837B2 (en) 2020-12-03
JP2018514590A (ja) 2018-06-07
SMT202200069T1 (it) 2022-03-21
US11597749B2 (en) 2023-03-07
JP6884755B2 (ja) 2021-06-09

Similar Documents

Publication Publication Date Title
EA202090184A3 (ru) Пептидные композиции и способы использования
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
IL279537A (en) Aav compositions
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112017010088A2 (pt) polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo
PT3500255T (pt) Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
DK4129321T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
HUE062587T2 (hu) Gyógyszerkészítmények peptid bejuttatására
CL2016002839A1 (es) Derivados de carboxamida
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX2018003445A (es) Expresion de proteinas que contienen fc.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
HUE061877T2 (hu) Ciklosporin-analógok gyógyszerkészítményei
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
BR112017002193A2 (pt) peptídeo derivado de urlc10 e vacina contendo o mesmo